Research has demonstrated that anti-LAG-3 therapy can improve T cell proliferation, rejuvenate exhausted cytotoxic T lymphocytes, and increase tumour infiltration in murine cancer models [19]. This evidence concerns the gene LAG3 and neoplasm.